MXPA05011626A - Procedimiento de soldificacion con antisolvente. - Google Patents

Procedimiento de soldificacion con antisolvente.

Info

Publication number
MXPA05011626A
MXPA05011626A MXPA05011626A MXPA05011626A MXPA05011626A MX PA05011626 A MXPA05011626 A MX PA05011626A MX PA05011626 A MXPA05011626 A MX PA05011626A MX PA05011626 A MXPA05011626 A MX PA05011626A MX PA05011626 A MXPA05011626 A MX PA05011626A
Authority
MX
Mexico
Prior art keywords
solidification process
organic
inorganic compound
antisolvent solidification
antisolvent
Prior art date
Application number
MXPA05011626A
Other languages
English (en)
Spanish (es)
Inventor
Cornelis Elizabeth Johann Lare
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33418418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05011626(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of MXPA05011626A publication Critical patent/MXPA05011626A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D3/00—Halides of sodium, potassium or alkali metals in general
    • C01D3/22—Preparation in the form of granules, pieces, or other shaped products
    • C01D3/24—Influencing the crystallisation process
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Glanulating (AREA)
  • Colloid Chemistry (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
MXPA05011626A 2003-04-29 2004-04-28 Procedimiento de soldificacion con antisolvente. MXPA05011626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46676103P 2003-04-29 2003-04-29
PCT/EP2004/004506 WO2004096405A1 (en) 2003-04-29 2004-04-28 Antisolvent solidification process

Publications (1)

Publication Number Publication Date
MXPA05011626A true MXPA05011626A (es) 2006-01-23

Family

ID=33418418

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011626A MXPA05011626A (es) 2003-04-29 2004-04-28 Procedimiento de soldificacion con antisolvente.

Country Status (22)

Country Link
US (4) US20060182808A1 (enExample)
EP (1) EP1620193B1 (enExample)
JP (1) JP5207432B2 (enExample)
KR (1) KR20060006949A (enExample)
CN (1) CN100434133C (enExample)
AR (1) AR044140A1 (enExample)
AT (1) ATE406946T1 (enExample)
AU (1) AU2004234057A1 (enExample)
BR (1) BRPI0409860A (enExample)
CA (1) CA2523883C (enExample)
CL (1) CL2004000912A1 (enExample)
DE (1) DE602004016311D1 (enExample)
ES (1) ES2312996T3 (enExample)
IL (1) IL171613A (enExample)
MX (1) MXPA05011626A (enExample)
MY (1) MY141189A (enExample)
NO (1) NO20055607L (enExample)
NZ (1) NZ543772A (enExample)
RU (1) RU2339364C2 (enExample)
TW (1) TW200500095A (enExample)
WO (1) WO2004096405A1 (enExample)
ZA (1) ZA200509597B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272438B2 (en) * 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
EP1906919A4 (en) * 2005-07-15 2012-12-26 Map Pharmaceuticals Inc MULTIPLE ACTIVE PHARMACEUTICAL PRINCIPLES COMBINED IN DISCRETE INHALATION PARTICLES AND THEIR FORMULATIONS
US7942990B2 (en) 2006-12-18 2011-05-17 Daicel Chemical Industries, Ltd. Hybrid inflator
EP2124633B1 (en) * 2007-01-22 2012-03-07 Cargill, Incorporated Method of producing purified rebaudioside a compositions using solvent/antisolvent crystallization
GB0705159D0 (en) * 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
FI120527B (fi) * 2007-06-18 2009-11-30 Crisolteq Oy Talteenottomenetelmä
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
TWI466709B (zh) * 2011-07-20 2015-01-01 Nat Univ Chung Hsing From the original berry Wolfberry a liquid - liquid freezing method for separation of high purity theaflavins palmitate Maize
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9452930B2 (en) * 2013-11-04 2016-09-27 New Jersey Institute Of Technology System and method for continuous polymer coating of particles
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN106853295A (zh) * 2015-12-09 2017-06-16 北大方正集团有限公司 一种基于膜分散的结晶方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10881123B2 (en) * 2017-10-27 2021-01-05 Frito-Lay North America, Inc. Crystal morphology for sodium reduction
JP6761560B2 (ja) * 2018-06-14 2020-09-23 日揮株式会社 晶析装置及び晶析方法
CN119679728A (zh) * 2018-12-28 2025-03-25 四川科伦药物研究院有限公司 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂
CN111234431A (zh) * 2020-03-31 2020-06-05 宁夏颐星新材料科技有限公司 一种消泡型聚乙烯醇粉末的生产工艺
GB202004824D0 (en) 2020-04-01 2020-05-13 Naturbeads Ltd Biopolymer particle preparation
GB202011836D0 (en) * 2020-07-30 2020-09-16 Micropore Tech Limited Crystallisation methods
CN115777906A (zh) * 2021-09-10 2023-03-14 吉林大学 氯化钠纳微米粒子及其制备方法和应用
AU2023408533A1 (en) 2022-12-22 2025-08-07 Nanomi B.V. Process for preparing stable nanoparticle and composition thereof
CN117942426B (zh) * 2024-03-22 2024-05-31 四川大学 一种具有取向孔道结构的多级多孔材料及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716453B1 (fr) * 1994-02-22 1996-03-29 Rhone Poulenc Agrochimie Procédé de sulfinylation de composés hétérocycliques.
US4089843A (en) * 1976-09-20 1978-05-16 The Upjohn Company Precipitating polymers in powder form
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
JPH0672528B2 (ja) * 1985-07-16 1994-09-14 三信工業株式会社 船舶のエンジン
RU2026670C1 (ru) * 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5269926A (en) * 1991-09-09 1993-12-14 Wisconsin Alumni Research Foundation Supported microporous ceramic membranes
FR2658498B1 (fr) * 1990-02-19 1992-05-15 Atochem Particules de chlorure de magnesium a structure tronc conique, composante catalytique supportee sur ces particules, polyolefines obtenues a partir de cette composante catalytique, procedes de fabrication de ces produits.
JP2555475B2 (ja) * 1990-10-16 1996-11-20 工業技術院長 無機質微小球体の製造方法
JP2816597B2 (ja) * 1990-11-28 1998-10-27 富士写真フイルム株式会社 溶液の均一混合装置および弾性体多孔膜
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive
WO1993000156A1 (fr) * 1991-06-29 1993-01-07 Miyazaki-Ken Emulsions monodispersees simples et doubles et procede de production
JP3722293B2 (ja) * 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
NZ276277A (en) * 1993-11-08 1998-04-27 Gillette Co Antiperspirant compound, in aerogel form, being an aluminium salt, a zirconium salt or an aluminium-zirconium salt
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
US6387399B1 (en) * 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5876480A (en) * 1996-02-20 1999-03-02 The United States Of America As Represented By The Secretary Of The Navy Synthesis of unagglomerated metal nano-particles at membrane interfaces
GB9610955D0 (en) * 1996-05-24 1996-07-31 Hercules Inc Sizing composition
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
EP1071402B1 (en) * 1998-04-09 2006-09-13 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
US6113795A (en) * 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN191236B (enExample) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6780507B2 (en) * 2000-02-09 2004-08-24 Analytical Research Systems, Inc. Hydrocapsules and method of preparation thereof
US6623761B2 (en) * 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US20030049323A1 (en) * 2001-08-29 2003-03-13 Hitt James E. Process to precipitate drug particles
HRP20040334A2 (en) * 2001-10-10 2004-08-31 Boehringer Ingelheim Pharma Powder processing with pressurized gaseous fluids
US6890592B2 (en) * 2002-03-13 2005-05-10 Appleton Papers Inc. Uniform microcapsules
US6966990B2 (en) * 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing

Also Published As

Publication number Publication date
CN100434133C (zh) 2008-11-19
ATE406946T1 (de) 2008-09-15
ES2312996T3 (es) 2009-03-01
DE602004016311D1 (de) 2008-10-16
EP1620193B1 (en) 2008-09-03
NO20055607D0 (no) 2005-11-28
CN1780670A (zh) 2006-05-31
AU2004234057A1 (en) 2004-11-11
CA2523883C (en) 2012-01-03
NZ543772A (en) 2009-05-31
US20060182808A1 (en) 2006-08-17
US20110268806A1 (en) 2011-11-03
RU2005136983A (ru) 2006-03-20
HK1088268A1 (en) 2006-11-03
JP2006524565A (ja) 2006-11-02
US20130131029A1 (en) 2013-05-23
US20120232296A1 (en) 2012-09-13
TW200500095A (en) 2005-01-01
BRPI0409860A (pt) 2006-05-16
NO20055607L (no) 2005-11-28
AR044140A1 (es) 2005-08-24
CL2004000912A1 (es) 2005-02-04
IL171613A (en) 2010-02-17
WO2004096405A1 (en) 2004-11-11
CA2523883A1 (en) 2004-11-11
KR20060006949A (ko) 2006-01-20
RU2339364C2 (ru) 2008-11-27
ZA200509597B (en) 2006-12-27
MY141189A (en) 2010-03-31
JP5207432B2 (ja) 2013-06-12
EP1620193A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
MY141189A (en) Antisolvent solidification process
AU2003225306A1 (en) Removal of chloramines from drinking water with improved activated carbon
DE60104454D1 (de) Einsatz sowie Giessformverfahren zum Übergiessen desselben
AP2005003368A0 (en) PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands.
ZA200704399B (en) Highly insulating and fireproof coating material for casting moulds
PL1689232T3 (pl) Sposób ochrony materiałów
MX2008000063A (es) Pildoras para perdida de fluidos.
DK1017684T3 (da) Kontrastmiddel til afbildning af infarkter og nekroser
PL371784A1 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
EP1300375A4 (en) THERMOPLASTIC HYDRAULIC COMPOSITION, PRODUCT PRODUCED THEREFROM BY HYDRATION CURING, AND PROCESS FOR PRODUCTION OF FA TERENE PRODUCT
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
FR2881426B1 (fr) Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
DE602004014955D1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)-ethylcyclohexanol-derivate als monoamin-wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
ATE252589T1 (de) Aluminosiloxanverbindungen und verfahren zu ihrer herstellung
TW200603880A (en) Antisolvent emulsion solidification process
DE502007002510D1 (de) Keramische Einbettmasse zur Herstellung einer Giessform sowie damit verbundene Herstellungsverfahren
WO2007047431A3 (en) Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors
WO2005047299A3 (de) Chirale di- und triphosphite
TW200714688A (en) Method for regenerating fluorescent material and fluorescent lamp
WO2007025994A3 (fr) Utilisation d'au moins un 2-alkyle furane, a titre de principe actif depigmentant ou eclaircissant
WO2004098488A3 (fr) Utilisation de dithiols dans une composition de deformation permanente des cheveux
ZA200309927B (en) Safety fluid injecting/sampling apparatus.
ATA10932002A (de) Schneckenpresse zum abtrennen von flüssigkeit aus feststoff-flüssigkeits-gemischen, insbesondere faserstoffsuspensionen
Atkins Plastic fittings provide a wide range of uses
HU0300066V0 (en) Munition, not harmful to people (for warning)

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
GB Transfer or rights
GB Transfer or rights